In 2024, India recorded more than 233,000 dengue cases and nearly 300 deaths, according to national surveillance figures reported by the government’s vector-borne disease control programme. The following year brought some relief, with cases declining to just below 122,000, although more than 130 deaths were still reported. Early data from 2026 has raised fresh concerns, as nearly 7,000 cases were recorded by the end of February, a level that would usually take significantly longer to reach. Public health officials have described the early rise as an unusual beginning to transmission, indicating that the traditional dengue calendar is shifting.
Against this changing backdrop, the approval of India’s first dengue vaccine represents a significant milestone. However, the central challenge for policymakers now lies not only in vaccine availability but also in ensuring that the healthcare system is prepared to deploy it effectively.
For decades, India’s dengue response has followed a repeated pattern. Cases increase during the monsoon season, hospitals experience a surge of fever patients, fogging campaigns intensify, and public attention reduces once rainfall declines. This cycle has continued with limited structural changes from one year to another.
The introduction of a vaccine creates an opportunity to move from a reactive approach toward a preventive and predictive public health model. This requires identifying outbreak-prone districts before cases rise sharply, reducing the number of infections that develop into severe disease, preparing region-specific response strategies, and directing resources toward prevention before healthcare facilities become overwhelmed.
The vaccine will need to function as part of a broader public health framework involving disease surveillance, mosquito control measures, and healthcare infrastructure planning rather than being considered a standalone solution.
Climate change has further complicated dengue control by altering the conditions that influence mosquito breeding and disease transmission. Rising temperatures are extending mosquito breeding periods, while unpredictable rainfall patterns are creating additional sources of stagnant water in areas that previously experienced limited exposure. Urban heat islands are also contributing to warmer nighttime conditions that allow mosquito activity to continue for longer periods.
These environmental changes are extending dengue transmission beyond the traditional monsoon season. Areas that historically recorded fewer cases, including higher-altitude and semi-arid regions, are now reporting dengue infections. As a result, surveillance systems based on fixed seasonal patterns are becoming less effective.
Climate-focused surveillance is increasingly necessary, with dengue monitoring, mosquito population mapping, and weather information integrated into a common decision-making system. The vaccine can strengthen this approach by adding another layer of protection alongside mosquito control, water management, and improved urban planning.
The implementation of the vaccine programme will require health authorities to address several critical questions. States may need to consider whether high-burden districts should receive priority during the initial rollout instead of adopting an immediate uniform national approach. Vaccination strategies may also need to be guided by disease patterns and scientific modelling rather than administrative convenience.
Authorities will also need to evaluate whether climate-risk assessments should influence vaccine distribution, particularly in regions showing signs of expanding dengue transmission. State health departments must determine how existing surveillance information can be used to act before outbreaks intensify rather than increasing emergency measures only after hospitals begin facing pressure.
These decisions will likely vary between states depending on local disease trends, healthcare capacity, and population density. The importance lies in addressing these challenges during the planning stage of vaccine implementation rather than after the system has already been established.
The success of India’s dengue vaccination strategy cannot be measured only through the number of doses administered. While vaccination coverage will remain an important indicator, the broader impact will depend on whether severe dengue cases decline in high-burden districts and whether healthcare systems begin responding to early warning signals before outbreaks reach critical levels.
A successful dengue strategy will require surveillance data to guide timely action, stronger prevention systems, and coordinated public health planning. If integrated effectively with existing measures, the vaccine could mark the beginning of a new approach focused on anticipating outbreaks rather than responding after they occur. The long-term impact of this milestone will depend on whether India can transform vaccine availability into a comprehensive and sustainable dengue control system.
About The Author
Comment List